ARQT
Arcutis Biotherapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.93B
P/E Ratio
—
EPS
$-0.13
Beta
1.77
52W High
$31.77
52W Low
$11.86
50-Day MA
$24.82
200-Day MA
$21.94
Dividend Yield
—
Profit Margin
-4.29%
Forward P/E
131.58
PEG Ratio
—
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in Westlake Village, California.
Fundamentals
| Revenue (TTM) | $376.07M |
| Gross Profit (TTM) | $339.38M |
| EBITDA | $-7.56M |
| Operating Margin | 14.20% |
| Return on Equity | -9.30% |
| Return on Assets | -1.96% |
| Revenue/Share (TTM) | $2.96 |
| Book Value | $1.54 |
| Price-to-Book | 15.47 |
| Price-to-Sales (TTM) | 7.80 |
| EV/Revenue | 7.51 |
| EV/EBITDA | 1586.60 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 81.50% |
| Shares Outstanding | $124.03M |
| Float | $91.90M |
| % Insiders | 1.71% |
| % Institutions | 108.66% |
Analyst Ratings
Consensus ($34.75 target)
2
Strong Buy5
Buy1
HoldData last updated: 4/7/2026